The Claim
Patients who are adherent to GLP-1 receptor agonist therapy experience greater reductions in body weight compared to those who are not adherent or are analyzed in an intention-to-treat or mixed population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People who consistently take GLP-1 receptor agonist medications lose more weight than those who do not take them regularly. This difference is observed when comparing patients who follow their treatment plan versus those who drop out or are analyzed in broader groups.
See the scientific wording
Adherence to GLP-1 receptor agonist therapy is associated with greater weight loss, as patients classified as treatment-adherent demonstrated the largest reductions in body weight compared to intention-to-treat or mixed populations.
The medication works by mimicking a natural hormone that tells your brain you are full and slows down how fast food leaves your stomach. People who take their medicine every day keep these signals active, so they feel less hungry and eat less over time, which leads to more weight loss.
What the research says
1 studyPeople who consistently take their GLP-1 medication lose more weight than those who don't, based on this study's comparison of different patient groups.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.